CDNA stock forecast, quote, news & analysis

Key Takeaways

• CareDx (CDNA) surged approximately 33.9% over the last 30 days, driven by Medicare's finalized coverage policy for its transplant surveillance testing portfolio.
• The Centers for Medicare & Medicaid Services (CMS) issued a favorable Local Coverage Determination (LCD) affirming reimbursement for AlloSure and AlloMap tests across kidney, heart, and lung transplant recipients.
• Strategic corporate actions — including the acquisition of Naveris and the divestiture of the Lab Products business — reshaped the company's focus on high-growth precision diagnostics.
• Q2 2026 earnings reported on July 30 showed 52% year-over-year revenue growth to $132 million, with full-year revenue guidance raised to $490–$500 million.
• BTIG raised its price target to $45 from $28 while maintaining a Buy rating, reflecting increased analyst conviction following the Medicare decision.

CareDx (CDNA) Company Overview and Market Position

CareDx, Inc. is a precision medicine diagnostics company focused on transplant care, specialty oncology, and cell therapy. Its core transplant surveillance portfolio includes AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung — non-invasive, blood-based molecular tests that detect organ rejection without the need for invasive biopsies. The company also provides digital health solutions and patient support services that span the entire transplant journey. With the July 2026 acquisition of Naveris, CareDx added NavDx, the first and only Medicare-covered molecular residual disease (MRD) test for HPV-positive head and neck and anal cancers, expanding its estimated U.S. addressable market to more than $12 billion. Investors closely track CDNA because Medicare reimbursement policy directly influences test utilization rates and, by extension, the company's revenue trajectory.

CareDx (CDNA) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 calendar days, CareDx shares climbed from a closing price of $28.50 on June 30, 2026, to $38.15 by July 30, 2026 — a gain of approximately 33.9%. The rally was punctuated by a single-day surge of 35.6% on July 16, when the Medicare LCD decision was announced and the stock closed at $40.34, a new 52-week high. Following that explosive move, shares consolidated in the $35–$40 range as investors awaited the Q2 earnings report.

Over the broader quarter, CDNA demonstrated sustained upward momentum. The stock opened the period near $27.85 (closing price on June 25) and appreciated roughly 37% through late July. The quarterly trend reflects a series of transformational events — the Lab Products divestiture, the Naveris acquisition close, the Medicare LCD finalization, and strong quarterly results — that collectively reinforced investor confidence in the company's strategic direction and revenue growth profile.

What Drove CDNA Stock Price in the Last 30 Days

The dominant catalyst behind the 30-day rally was the July 16 announcement that CMS finalized the Medicare Local Coverage Determination for molecular testing related to solid organ allograft rejection. The final policy affirmed coverage for CareDx's entire transplant surveillance portfolio — AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung — with defined testing frequency limits across kidney, heart, and lung transplant recipients. For kidney patients, the policy allows up to six surveillance tests in the first year post-transplant and four per year in years two and three. Heart and lung recipients are eligible for up to 12 tests in year one and four annually thereafter. Analysts characterized these limits as "generous" and well above current utilization levels, removing a major reimbursement overhang that had weighed on the stock.

Additional catalysts reinforced the bullish narrative. On July 1, CareDx completed the acquisition of Naveris, bringing the NavDx oncology MRD test under its umbrella and expanding into specialty oncology. Simultaneously, the company closed the $171.2 million sale of its Lab Products business to Eurobio Scientific on June 30, sharpening its strategic focus on U.S. precision medicine testing services. On the analyst front, BTIG's Mark Massaro raised the price target to $45 from $28 and maintained a Buy rating. The July 30 Q2 earnings report confirmed the operational momentum: revenue of $132 million (up 52% year-over-year), testing services revenue of $100 million (up 61%), and adjusted EBITDA of $25 million. Management raised full-year 2026 revenue guidance to $490–$500 million and adjusted EBITDA guidance to $66–$78 million.

What Drove CDNA Stock Performance Over the Last Quarter

The quarterly performance of CDNA was shaped by a deliberate corporate transformation. The sale of the Lab Products business to Eurobio Scientific, which closed on June 30, eliminated a lower-margin segment and generated significant cash proceeds. The April-announced Naveris acquisition, which closed on July 1, positioned CareDx in the high-growth oncology diagnostics market with a commercially validated, Medicare-covered product. These strategic moves reframed CareDx as a pure-play precision diagnostics company with exposure to transplant, oncology, and cell therapy. The Medicare LCD finalization in mid-July served as the culminating event of the quarter, providing regulatory clarity that allowed investors to model future testing services revenue with greater confidence. The Q2 earnings report on July 30 validated this optimism with record revenue, improved profitability, and upwardly revised guidance.

Trending AI Robots

For investors seeking data-driven trading strategies, Tickeron offers a dedicated Trending AI Robots page featuring a curated selection of top-performing AI-powered trading bots. While Tickeron's platform hosts hundreds of bots trading thousands of tickers across equities, ETFs, and cryptocurrencies, only the most relevant and consistently strong performers appear in this section. Each bot operates on a distinct strategy — ranging from short-term momentum plays to longer-duration trend-following models — and is evaluated on metrics including win rate, Sharpe ratio, and overall return. Traders and investors can browse the page to identify bots aligned with their own risk tolerance and time horizon.

CDNA Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors will influence CDNA's trajectory. The Medicare LCD takes effect on August 30, 2026, and subsequent quarterly reports will reveal whether the coverage clarity translates into higher testing volumes. Integration of the Naveris acquisition and the ramp-up of NavDx revenue will be closely monitored starting in Q3 2026. The company's AlloHeme pipeline program, targeting cell therapy applications, represents a longer-term growth opportunity as it progresses toward CLIA readiness. On the risk side, the finalized LCD hard-codes test-frequency limits, and any shift in commercial payer behavior or bundled payment models could affect pricing and utilization. Competitive dynamics also warrant attention — NTRA (Natera) competes in the kidney transplant space with its Prospera test. Additionally, with CDNA trading at a forward P/E multiple that analysts consider elevated, execution on the raised guidance will be essential to sustaining valuation levels.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations